| Literature DB >> 34917764 |
B C Richard1,2, T A Bayer1,2, S Bergström Lind3, G Shevchenko3, J Bergquist3.
Abstract
In the field of Alzheimer's disease, there is an urgent need for novel analytical tools to identify disease-specific biomarkers and to evaluate therapeutics. Preclinical trials commonly employ amyloid beta (Aβ) peptide signatures as a read-out. In this paper, we report a simplified and detailed protocol for robust immunoprecipitation of Aβ in brain tissue prior to mass spectrometric detection exemplified by a study using transgenic mice. The established method employed murine monoclonal and rabbit polyclonal antibodies and was capable of yielding well-reproducible peaks of high intensity with low background signal intensities corresponding to various Aβ forms.Entities:
Keywords: AD, Alzheimer’s disease; APP, amyloid precursor protein; Amyloid beta peptides; Aβ, amyloid beta; BSA, bovine serum albumine; Brain; FA, formic acid; IP, Immunoprecipitation; Immunoprecipitation; MALDI-TOF MS; MALDI-TOF MS, matrix-assisted-laser-desorption time-of-flight mass spectrometry; MS, mass spectrometry; PBS, phosphate buffered saline; S/N, signal-to-noice ratio; SA, sinapinic acid; VD, volume of Dynabeads suspension; Wt, wild type
Year: 2019 PMID： 34917764 PMCID： PMC8669460 DOI： 10.1016/j.clinms.2019.07.001
Source DB: PubMed Journal: Clin Mass Spectrom ISSN： 2213-8005